hVIVO (LON:HVO) Shares Down 6.8% – What’s Next?

hVIVO plc (LON:HVO) shares traded down 6.8% on Thursday . The company traded as low as GBX 19 ($0.24) and last traded at GBX 19.10 ($0.24). 2,268,262 shares traded hands during trading, a decline of 33% from the average session volume of 3,389,765 shares. The stock had previously closed at GBX 20.50 ($0.26).

hVIVO Stock Performance

The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The stock’s 50-day moving average price is GBX 23.58 and its 200-day moving average price is GBX 26.77. The company has a market cap of £129.95 million, a P/E ratio of 636.67 and a beta of 0.97.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.